prikaz prve stranice dokumenta Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
  Download
PDF 1.06 MB
Scientific paper - Original scientific paper
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
Journal of Psychopharmacology, 38 (2024), 4; 395-403. https://doi.org/10.1177/02698811241237868
Papić, Ivan; Bistrović, Petra; Krečak, Ivan; Ortner Hadžiabdić, Maja; Lucijanić, Marko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Papić, I., Bistrović, P., Krečak, I., Ortner Hadžiabdić, M. & Lucijanić, M. (2024). Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology, 38. (4), 395-403. doi: 10.1177/02698811241237868

Papić, Ivan, et al. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology, vol. 38, no. 4, 2024, pp. 395-403. https://doi.org/10.1177/02698811241237868

Papić, Ivan, Petra Bistrović, Ivan Krečak, Maja Ortner Hadžiabdić and Marko Lucijanić. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology 38, no. 4 (2024): 395-403. https://doi.org/10.1177/02698811241237868

Papić, I., et al. (2024) 'Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use', Journal of Psychopharmacology, 38(4), pp. 395-403. doi: 10.1177/02698811241237868

Papić I, Bistrović P, Krečak I, Ortner Hadžiabdić M, Lucijanić M. Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology [Internet]. 2024 March 13 [cited 2024 December 30];38(4):395-403. doi: 10.1177/02698811241237868

I. Papić, P. Bistrović, I. Krečak, M. Ortner Hadžiabdić and M. Lucijanić, "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use", Journal of Psychopharmacology, vol. 38, no. 4, pp. 395-403, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:413758. [Accessed: 30 December 2024]

Metadata
Title (english)Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
AuthorIvan Papić
AuthorPetra Bistrović
AuthorIvan Krečak
AuthorMaja Ortner Hadžiabdić
AuthorMarko Lucijanić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Due to non-consistent reports in the literature, there are uncertainties about the potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) in patients with Coronavirus disease 2019 (COVID-19). Aim: To investigate associations of SSRIs with clinical characteristics and unwanted outcomes among real-life severe and critical COVID-19 patients and their relationship with remdesivir (RDV) use. Methods: This retrospective cohort study evaluated a total of 1558 COVID-19 patients of the white race treated in a tertiary center institution, among them 779 patients treated with RDV and 779 1:1 case-matched patients. Results: A total of 78 (5%) patients were exposed to SSRIs during hospitalization, similarly distributed among patients treated with RDV and matched patients (5.1 and 4.9%). No significant associations of SSRI use with age, sex, comorbidity burden, and COVID-19 severity were present in either of the two cohorts (p > 0.05 for all analyses). In multivariate analyses adjusted for clinically meaningful variables, SSRI use was significantly associated with higher mortality among RDV (adjusted odds ratio (aOR) 2.0, p = 0.049) and matched patients (aOR 2.22, p = 0.044) and with higher risk for mechanical-ventilation (aOR 2.57, p = 0.006), venous-thromboembolism (aOR 3.69, p = 0.007), and bacteremia (aOR 2.22, p = 0.049) among RDV treated patients. Conclusions: Adverse outcomes associated with SSRI use in COVID-19 patients might be potentiated by RDV use, and clinically significant interactions between these two drug classes might exist. Although our findings raise important considerations for clinical practice, they are limited by retrospective nature of the study, lack of ethnic diversity, and the potential for unmeasured confounding factors. Future studies exploring underlying biological mechanisms are needed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Psychopharmacology
Numberingvol. 38, no. 4, pp. 395-403
p-ISSN0269-8811
e-ISSN1461-7285
DOIhttps://doi.org/10.1177/02698811241237868
URN:NBNurn:nbn:hr:105:413758
Publication2024-03-13
Document URLhttps://journals.sagepub.com/doi/10.1177/02698811241237868
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-11-25 08:47:52